Conference Coverage

VIDEO: Is anastrozole or tamoxifen best for secondary prevention of DCIS?


 

AT SABCS 2015

References

SAN ANTONIO – Two large phase III randomized trials comparing anastrozole and tamoxifen for prevention of disease recurrence in postmenopausal women with ductal carcinoma in situ were presented at the San Antonio Breast Cancer Symposium.

In an interview, Dr. Anthony Howell, professor of medical oncology at the University of Manchester, England, provides the key take-home lessons from the NSABP B-35 and IBIS-II DCIS trials.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

bjancin@frontlinemedcom.com

Recommended Reading

High risk for getting breast cancer linked with low risk of metastasis
MDedge Hematology and Oncology
VIDEO: Win-win with denosumab as adjuvant therapy for post-menopausal breast cancer
MDedge Hematology and Oncology
SABCS: CREATE-X – Capecitabine is efficacious against residual HER2-negative breast cancer
MDedge Hematology and Oncology
VIDEO: Adjuvant capecitabine has role for residual disease after neoadjuvant therapy
MDedge Hematology and Oncology
VIDEO: Triple-negative breast cancer outcomes boosted by adding carboplatin to neoadjuvant chemo
MDedge Hematology and Oncology
VIDEO: Mastectomy plus reconstruction has highest complication rates of all early BC treatment options
MDedge Hematology and Oncology
VIDEO: APOBEC3B enzyme may limit tamoxifen efficacy
MDedge Hematology and Oncology
VIDEO: Time to skip chemo for luminal A tumors?
MDedge Hematology and Oncology
VIDEO: Estrogen receptor gene mutations linked to poorer survival
MDedge Hematology and Oncology
VIDEO: Beta-blocker prevented trastuzumab-related drop in LVEF
MDedge Hematology and Oncology